Prevenar

Pre-clinicalCompleted

1 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Otitis Media

Conditions

Otitis Media, Otitis Media With Effusion, Pneumococcal Infections

Trial Timeline

Sep 1, 2005 → Jun 1, 2006

NCT ID

NCT00195611

About Prevenar

Prevenar is a pre-clinical stage product being developed by Pfizer for Otitis Media. The current trial status is completed. This product is registered under clinical trial identifier NCT00195611. Target conditions include Otitis Media, Otitis Media With Effusion, Pneumococcal Infections.

What happened to similar drugs?

2 of 12 similar drugs in Otitis Media were approved

Approved (2) Terminated (2) Active (8)

🔄ofloxacin otic solution 0.3%Daiichi SankyoPhase 3

🔄levofloxacinJohnson & JohnsonPhase 3

🔄levofloxacin; amoxicillin/clavulanateJohnson & JohnsonPhase 3

🔄V114MerckPhase 3

✅Montelukast + PlaceboMerckApproved

🔄7-valent pneumococcal-CRM197 conjugate vaccine + 7-valent pneumococcal-OMPC conjugate vaccineMerckPhase 3

🔄ZmaxPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00195611	Pre-clinical	Completed	Sep 1, 2005	Jun 1, 2006	Otitis Media
NCT00276107	Approved	Completed	Dec 1, 2004	Dec 1, 2005	Pneumococcal Infections
NCT00195390	Pre-clinical	Completed	Jul 1, 2004	Jul 1, 2008	Pneumococcal Infections

Competing Products

15 competing products in Otitis Media

See all competitors

Product	Company	Stage	Hype Score
piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1% + piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1% + piperacillin 2% + tazobactam 0.25% + piperacillin 4% + tazobactam 0.5% + piperacillin 8% + tazobactam 1.0%	Yuhan	Phase 1/2	24
ofloxacin otic solution 0.3%	Daiichi Sankyo	Phase 3	40
levofloxacin	Johnson & Johnson	Phase 3	40
levofloxacin; amoxicillin/clavulanate	Johnson & Johnson	Phase 3	40
V114	Merck	Phase 3	40
Montelukast + Placebo	Merck	Approved	43
7-valent pneumococcal-CRM197 conjugate vaccine + 7-valent pneumococcal-OMPC conjugate vaccine	Merck	Phase 3	40
Zmax	Pfizer	Phase 3	40
Observational	Pfizer	Pre-clinical	26
Saline + Fentanyl + Dexmedetomidine + Dexmedetomidine	Pfizer	Approved	43
amoxicillin/clavulanate postassium (Augmentin ES-600) + azithromycin SR	Pfizer	Phase 3	40
60 mg/kg azithromycin ER + 30 mg/kg azithromycin IR	Pfizer	Phase 2	35
Telithromycin (HMR3647)	Sanofi	Phase 3	40
telithromycin (HMR3647)	Sanofi	Phase 3	32
Telithromycin + Azithromycin	Sanofi	Phase 3	32